Technical Analysis for KYMR - Kymera Therapeutics, Inc.

Grade Last Price % Change Price Change
D 33.97 -3.27% -1.15
KYMR closed down 3.27 percent on Friday, April 19, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 2
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -3.27%
Bullish Engulfing Bullish -3.27%
Oversold Stochastic Weakness -3.27%
Lower Bollinger Band Walk Weakness 0.62%
Gapped Up Strength 0.62%
Down 3 Days in a Row Weakness 0.62%
Down 4 Days in a Row Weakness 0.62%
Oversold Stochastic Weakness 0.62%
NR7 Range Contraction 0.12%

   Recent Intraday Alerts

Alert Time
Down 5% about 19 hours ago
Slingshot Bearish Entry about 19 hours ago
Fell Below Previous Day's Low about 19 hours ago
Down 3% about 19 hours ago
Possible Inside Day about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Autoimmunity Rheumatoid Arthritis Hematologic Malignancies Atopic Dermatitis Dermatitis Hidradenitis Suppurativa

Is KYMR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.31
52 Week Low 9.6
Average Volume 649,135
200-Day Moving Average 25.34
50-Day Moving Average 39.01
20-Day Moving Average 37.01
10-Day Moving Average 35.33
Average True Range 1.86
RSI (14) 37.89
ADX 26.04
+DI 13.20
-DI 21.26
Chandelier Exit (Long, 3 ATRs) 36.32
Chandelier Exit (Short, 3 ATRs) 38.74
Upper Bollinger Bands 41.46
Lower Bollinger Band 32.56
Percent B (%b) 0.16
BandWidth 24.03
MACD Line -1.37
MACD Signal Line -1.03
MACD Histogram -0.3403
Fundamentals Value
Market Cap 2.02 Billion
Num Shares 59.4 Million
EPS -2.86
Price-to-Earnings (P/E) Ratio -11.88
Price-to-Sales 46.41
Price-to-Book 5.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.24
Resistance 3 (R3) 37.40 36.46 36.70
Resistance 2 (R2) 36.46 35.63 36.39 36.51
Resistance 1 (R1) 35.22 35.12 34.75 35.06 36.33
Pivot Point 34.28 34.28 34.05 34.21 34.28
Support 1 (S1) 33.04 33.45 32.57 32.88 31.61
Support 2 (S2) 32.10 32.94 32.03 31.43
Support 3 (S3) 30.86 32.10 31.25
Support 4 (S4) 30.70